Skip to main content
Study compares health outcomes with degludec, glargine in diabetes

Researchers evaluated 7,637 type 2 diabetes patients, mean age of 65, and found that 8.5% of those on degludec experienced a major cardiovascular event and 4.9% had prespecified adjudicated severe hypoglycemia, compared with 9.3% and 6.6% of those on glargine, respectively. The findings, published in The New England Journal of Medicine and presented at the American Diabetes Association's meeting, also revealed a significantly lower fasting plasma glucose level among those who received degludec than those in the glargine group.

Full Story: